Dyne Therapeutics, INC Form 4 insider transactions

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 1,390 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,339 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock on September 16 and 17, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 1,468 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, exercised stock options and sold shares on September 6, 2024.

Director Dirk Kersten reports the sale of 1,577 shares of Dyne Therapeutics (DYN) common stock at an average price of $35.03.

Dyne Therapeutics CEO John Cox indirectly acquired shares of common stock through trust accounts, signaling confidence in the company's future.

Director Dirk Kersten reports selling shares of Dyne Therapeutics under a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer of Dyne Therapeutics, Douglas Kerr, reports acquisition of common stock and stock options.

Chief Commercial Officer Johanna Friedl-Naderer reports the acquisition of Dyne Therapeutics common stock and stock options.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through entities he is associated with, under a pre-arranged trading plan.

Director Dirk Kersten reports the sale of Dyne Therapeutics (DYN) shares held by Forbion Capital Fund IV Cooperatief U.A. under a pre-arranged 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through entities he is associated with, under a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a Rule 10b5-1 trading plan.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Dyne Therapeutics' Chief Medical Officer, Wildon Farwell, sold shares of common stock on August 19, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Director Dirk Kersten reports the sale of Dyne Therapeutics (DYN) shares held by Forbion Capital Fund IV Cooperatief U.A. and ForDyne B.V. through a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through Forbion Capital Fund IV Cooperatief U.A. and other related entities.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through a Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through a pre-arranged Rule 10b5-1 trading plan.

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a pre-arranged Rule 10b5-1 trading plan.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, files an amended Form 4 to correct the number of stock options exercised and shares sold.

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, exercised stock options and sold shares of common stock on June 21 and June 24, 2024, according to a Form 4 filing with the SEC.

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,136 shares of common stock on June 11, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.